Cart

YOUR CART IS EMPTY

Add research compounds to begin your order.

Human controlled primary / post hocModerate; exploratory kidney evidenceCompleted; peer reviewed

SURPASS-4 and post-hoc kidney analysis

TIRZEPATIDE-STUDY-P037-P092

Del Prato et al. (2021); Heerspink et al. (2022), SURPASS-4.

Study design

Record details

Design: Randomized, open-label phase 3 trial with a post-hoc kidney analysis.
Population or model: People with type 2 diabetes and increased cardiovascular risk.
Material tested: Lilly-manufactured tirzepatide clinical product.
Comparator: Insulin glargine.

Evidence record

Endpoints, findings, and limitations

Endpoints

Glycated hemoglobin and post-hoc kidney endpoints, including biomarker-containing composites.

Qualified findings

The program supports diabetes evidence and a narrower post-hoc kidney signal.

Limitations

The cardiovascular observations were not a definitive cardiovascular outcomes trial. Kidney findings are post hoc and include biomarker-containing composites.

Reports and sources

Reference ledger

P037Human controlled primary, PEER REVIEWED

Del Prato et al. 2021 SURPASS-4

(2021). DOI: 10.1016/S0140-6736(21)02188-7
P092Human controlled primary, POST HOC; PEER REVIEWED

Heerspink et al. 2022 SURPASS-4 kidney analysis

(2022). DOI: 10.1016/S2213-8587(22)00243-1